Literature DB >> 21245426

Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.

James M G Larkin, Rosalie A Fisher, Lisa M Pickering, S Aslam Sohaib, Marwan Ghosn, Tim Christmas, Ruth L M Cordiner, Martin E Gore.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21245426     DOI： 10.1200/JCO.2010.33.4375

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  [Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")].

Authors:  M M Heck; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

Review 2.  Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?

Authors:  Laurence Albiges; Vincent Molinie; Bernard Escudier
Journal:  Oncologist       Date:  2012-07-17

3.  Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.

Authors:  Daniel Keizman; David Sarid; Jae L Lee; Avishay Sella; Maya Gottfried; Hans Hammers; Mario A Eisenberger; Michael A Carducci; Victoria Sinibaldi; Victoria Neiman; Eli Rosenbaum; Avivit Peer; Avivit Neumann; Wilmosh Mermershtain; Keren Rouvinov; Raanan Berger; Ibrahim Yildiz
Journal:  Oncologist       Date:  2016-07-05

4.  Targeting the mTOR pathway in Chromophobe Kidney Cancer.

Authors:  Brian Shuch; Srinivas Vourganti; Julia C Friend; Lee M Zehngebot; W Marston Linehan; Ramaprasad Srinivasan
Journal:  J Cancer       Date:  2012-04-02       Impact factor: 4.207

5.  Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma.

Authors:  Balaji Venugopal; Jawaher Ansari; Michael Aitchison; Lye Mun Tho; Roderick Campbell; Rob J Jones
Journal:  BMC Urol       Date:  2013-05-21       Impact factor: 2.264
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.